| Reviewer | Recommendation |
| IPOWatch | May Apply |
| Dilip Davda | Not Rated |
| Krijuna Research | Apply |
| Ventura Securities | Apply |
| Stoxbox | Apply |
| GEPL Capital | Not Rated |
| Choice Broking | Apply |
| BP Equities | Apply |
| Bajaj Broking | Apply |
| Antique Stock Broking | Apply |
| Anand Rathi | Apply |
| SMC Global | Neutral |
The firm has introduced various innovative products over the years, such as Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders), which are backed by 72 clinical studies and are widely known in over 76 countries across Europe, Asia, and other regions.
For medium-term investment, this IPO might be a good fit. Overall, investors should carefully evaluate the company’s fundamentals, strengths, risks, and growth prospects before deciding whether to invest.
Strengths:
- The firm develops advanced medical devices that require specialized technology supported by strong clinical evidence with high entry barriers.
- The company is backed by 2 research and development (“R&D”) facilities consisting of 156 qualified professionals to develop and improve medical products across different categories.
- Sahajanand Medical operates 3 integrated manufacturing facilities located in Surat and Hyderabad in India and in Nonthaburi in Thailand.
- The firm is backed by reputed institutional investors and an experienced management team who have years of experience across medical devices R&D, manufacturing, business development, quality assurance, quality control, and human resources sectors.
Weaknesses:
- Its manufacturing facilities involve certain risks such as quality control issues, disruptions in infrastructure facilities, and obsolete plant and machinery, which can lead to increased costs or interrupt its operations, negatively impacting its reputation and sales.
- The company is dependent on its top 10 suppliers for 63.61% of its raw materials. Loss of any of the top suppliers, delay, or sudden increase in the price of raw materials can adversely affect the overall business and cash flow.
- About 61% of the company’s revenue is derived from the sale of Vascular Intervention devices, especially its one product, Supraflex Cruz, which derives most of its revenue. If the sale of this product declines, then it can adversely impact the overall business, profit, and revenue.
Disclaimer
Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.
